18F-flumazenil: A g-aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsy

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1270-1277

  Vivash, Lucy ^a   Gregoire, Marie Claude ^b   Lau, Eddie W ^c   Ware, Robert E ^c   Binns, David ^c   Roselt, Peter ^c   Bouilleret, Viviane ^a   Myers, Damian E ^a   Cook, Mark J ^a   Hicks, Rodney J ^c   O'Brien, Terence J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

18F flumazenil; FDG; Fluorodeoxyglucose; Positron emission tomography; Temporal lobe epilepsy

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; FLUMAZENIL F 18; FLUORODEOXYGLUCOSE F 18; TRACER; UNCLASSIFIED DRUG; 2 AMINOBUTYRIC ACID; 2' FLUOROFLUMAZENIL; 2'-FLUOROFLUMAZENIL; ALPHA-AMINOBUTYRIC ACID; AMINOBUTYRIC ACID DERIVATIVE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUMAZENIL; FLUORODEOXYGLUCOSE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN MAPPING; BRAIN SIZE; BRAIN SURGERY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ERROR; DRUG TOLERABILITY; DRUG UPTAKE; EPILEPTIC FOCUS; FEMALE; HIPPOCAMPAL SCLEROSIS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PET SCANNER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; SENSITIVITY AND SPECIFICITY; TEMPORAL LOBE EPILEPSY; TREATMENT OUTCOME; 18F-FLUMAZENIL; CASE CONTROL STUDY; DRUG RESISTANCE; FDG; METABOLISM; METHODOLOGY; MIDDLE AGED; SCINTISCANNING;

18F-FLUMAZENIL; FDG; FLUORODEOXYGLUCOSE; POSITRON EMISSION TOMOGRAPHY; TEMPORAL LOBE EPILEPSY;

ADOLESCENT; ADULT; AGED; AMINOBUTYRATES; CASE-CONTROL STUDIES; DRUG RESISTANCE; EPILEPSY, TEMPORAL LOBE; FEMALE; FLUMAZENIL; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84881423726     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.107359     Document Type: Article

References (24)

1. Kilpatrick C, O'Brien T, Matkovic Z, Cook M, Kaye A. Preoperative evaluation for temporal lobe surgery. J Clin Neurosci. 2003;10:535-539.
2. Bouilleret V, Valenti MP, Hirsch E, Semah F, Namer IJ. Correlation between PET and SISCOM in temporal lobe epilepsy. J Nucl Med. 2002;43:991-998.
3. Vinton AB, Carne R, Hicks RJ, et al. The extent of resection of FDG-PET hypometabolism relates to outcome of temporal lobectomy. Brain. 2007;130: 548-560.
4. O'Brien TJ, Miles K, Ware R, Cook MJ, Binns DS, Hicks RJ. The cost-effective use of 18F-FDG PET in the presurgical evaluation of medically refractory focal epilepsy. J Nucl Med. 2008;49:931-937.
5. Hand KS, Baird VH, Van Paesschen W, et al. Central benzodiazepine receptor autoradiography in hippocampal sclerosis. Br J Pharmacol. 1997;122: 358-364.
6. 11C]flumazenil PET in temporal lobe epilepsy with unilateral and bilateral hippocampal sclerosis. Brain. 1997;120:1865-1876.
7. 18F]fluorodeoxyglucose-PET and MR imaging in refractory partial epilepsy: a prospective study in 100 patients. Brain. 1998;121:2067-2081.
8. 11C]flumazenil kinetics studied by PET: application to a critical study of the equilibrium approaches. J Cereb Blood Flow Metab. 1993;13:454-468.
9. 11C]flumazenil metabolite measurement in plasma is not necessary for accurate brain benzodiazepine receptor quantification. Eur J Nucl Med. 2000;27:1674-1683.
10. Dedeurwaerdere S, Gregoire MC, Vivash L, et al. In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat. Eur J Nucl Med Mol Imaging. 2009;36:958-965.
11. 18F]fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors. Eur J Nucl Med. 2001;28:1463-1470.
12. 11C]flumazenil. Neuroimage. 2009;45:891-902.
13. 18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. Nucl Med Biol. 2005;32:109-116.
14. Gilliam F, Faught E, Martin R, et al. Predictive value of MR imaging-identified mesial temporal sclerosis for surgical outcome in temporal lobe epilepsy: an intent-to-treat analysis. Epilepsia. 2000;41:963-966.
15. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279-287.
16. 11C]flumazenil-PET study. Brain. 2005;128:1330-1343.
17. Babb JL, Pretorius JK. Pathological substrates of epilepsy. In: Wyllie E, ed. The Treatment of Epilepsy: Principles and Practice. Philadelphia, PA: Lippincott, Williams & Wilkins 1993, 55-70.
18. 11C-flumazenil PET, volumetric MR imaging, and quantitative pathology in mesial temporal lobe epilepsy. Neurology. 1997;49:764-773.
19. Szelies B, Weber-Luxenburger G, Mielke R, et al. Interictal hippocampal benzodiazepine receptors in temporal lobe epilepsy: comparison with coregistered hippocampal metabolism and volumetry. Eur J Neurol. 2000;7:393-400.
20. 11C]flumazenil PET in temporal lobe epilepsy: do we need an arterial input function or kinetic modeling? J Cereb Blood Flow Metab. 2008;28:207-216.
21. 11C-flumazenil positron emission tomography in intractable temporal lobe epilepsy. Neurol India. 2004; 52:457-462.
22. Henry TR, Frey KA, Sackellares JC, et al. In vivo cerebral metabolism and central benzodiazepine-receptor binding in temporal lobe epilepsy. Neurology. 1993;43:1998-2006.
23. 11C]flumazenil positron emission tomography visualizes frontal epileptogenic regions. Epilepsia. 1995;36:1225-1232.
24. Ryvlin P, Bouvard S, Le Bars D, Mauguiere F. Transient and falsely lateralizing flumazenil-PET asymmetries in temporal lobe epilepsy. Neurology. 1999;53: 1882-1885.